Head to Head Survey: Reata Pharmaceuticals (RETA) and Uniqure (QURE)

Reata Pharmaceuticals (NASDAQ: RETA) and Uniqure (NASDAQ:QURE) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability and earnings.

Risk & Volatility

Reata Pharmaceuticals has a beta of -2.52, suggesting that its stock price is 352% less volatile than the S&P 500. Comparatively, Uniqure has a beta of 0.57, suggesting that its stock price is 43% less volatile than the S&P 500.

Valuation and Earnings

This table compares Reata Pharmaceuticals and Uniqure’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Reata Pharmaceuticals $49.86 million 13.54 -$6.22 million ($1.53) -16.90
Uniqure $25.10 million 22.19 -$73.37 million ($2.61) -6.93

Reata Pharmaceuticals has higher revenue and earnings than Uniqure. Reata Pharmaceuticals is trading at a lower price-to-earnings ratio than Uniqure, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Reata Pharmaceuticals and Uniqure’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Reata Pharmaceuticals -69.44% N/A -34.36%
Uniqure -338.39% -170.28% -40.50%

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Reata Pharmaceuticals and Uniqure, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Reata Pharmaceuticals 0 0 8 0 3.00
Uniqure 0 2 6 0 2.75

Reata Pharmaceuticals presently has a consensus price target of $54.71, suggesting a potential upside of 111.58%. Uniqure has a consensus price target of $19.86, suggesting a potential upside of 9.83%. Given Reata Pharmaceuticals’ stronger consensus rating and higher possible upside, research analysts plainly believe Reata Pharmaceuticals is more favorable than Uniqure.

Insider & Institutional Ownership

29.5% of Reata Pharmaceuticals shares are held by institutional investors. Comparatively, 25.0% of Uniqure shares are held by institutional investors. 44.0% of Reata Pharmaceuticals shares are held by company insiders. Comparatively, 0.7% of Uniqure shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Reata Pharmaceuticals beats Uniqure on 11 of the 14 factors compared between the two stocks.

Reata Pharmaceuticals Company Profile

Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases. The Company’s lead product candidates include bardoxolone methyl, which is being studied in Phase III trial for the treatment of pulmonary arterial hypertension (PAH), associated with connective tissue disease (CTD-PAH), as well as a Phase II trial for the treatment of pulmonary hypertension due to interstitial lung disease (PH-ILD), and PAH, each of which are subsets of pulmonary hypertension (PH), Omaveloxolone, which is in Phase II clinical development for the treatment of multiple diseases, including Friedreich’s ataxia, mitochondrial myopathies and metastatic melanoma.

Uniqure Company Profile

Uniqure NV is a gene therapy company based in the Netherlands. The Company is engaged in the discovery, development and commercialization of single treatments with curative results for patients suffering from genetic and other severe diseases. The Company advances a focused pipeline of gene therapies that are developed both internally and through partnerships. The Company’s product candidates within the Core Program include AMT-061 for Hemophilia B, AMT-130 for Huntington’s disease and S100A1 for congestive heart failure. The Company, through its collaboration with Bristol Myers-Squibb (BMS), is focused on building a portfolio of gene therapies led by the S100A1 program for congestive heart failure.

Receive News & Ratings for Reata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit